Similar User
@AlcazerVincent
@RemyDulery
@AIHemato
@thomas_cluzeau
@jjkiladjian
@NicBoissel
@PerrotAurore
@NStockerSAT
@ASchavgoulidze
@HouotRoch
@VivreAvecUneNmp
@anisiia_luchkiv
@HematoLa
@QuesnelBruno1
@nivallet
Exciting news for adult B-ALL patients! @US_FDA approves obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia fda.gov/drugs/resource… @ryancassaday
My friend @ElilasBen presented at @CARTday_meeting in Lille the data on leukapheresed patients who could not receive CAR T cells. Rarely discussed data. Thank you and congratulations for your great presentation.👏 #CARTDAY #Lille
Discover the top-cited articles of 2024 in Transplantation and Cellular Therapy. These selections highlight key advancements in hematopoietic cell transplantation and related therapies. Access the collection here: astctjournal.org/2024-top-cited… #HCT #GVHD #Lymsm
@at_Mitralab and I are excited to announce that registration is now open for the 8th edition of CARTday. Please follow the official account of the event @CARTday_meeting to get updated on this international exciting event. @SFGM_TC cartday.org/program-2024/
🚨 hot off the press 🚨 A (perhaps) underestimated aspect of CAR T-cell therapy: non-relapse mortality. Check out our new meta-analysis on this clinically relevant topic - out today in @NatureMedicine ! nature.com/articles/s4159… Let’s take a deeper dive! Start 🧵
3-yr follow-up of TRANSFORM @mana1981 #ASCO24: - mEFS 30 mos, mPFS & OS NR - mDOR also NR - 62% of patients crossed over to liso-cel from SOC arm Look at those KM curves! 😍 #lymsm
Published in @Hemasphere_EHA today! Treatment outcomes in patients with large B‐cell lymphoma after progression to #CART Great Spain+UK joint effort, big thanks to @KuhnlAndrea @ab_pau @JosuIraola1 @VictorNavarro32 and all participating colleagues! onlinelibrary.wiley.com/doi/full/10.10…
Save the date! The 8th edition of the international symposium on CAR T-cell therapy is going to take place in Lille, France after the olympic games on October 17-18, 2024. Check the preprogram below cartday.org -@SFGM_TC @at_Mitralab cartday.org/program-2024/
Save the date, 8th edition of international symposium on CAR T-cell therapy. The first international meeting ever! cartday.org
Thank you to @ASTCT for awarding our work. Many thanks to the co-authors and a special MERCI to @drjgauthier I was lucky to met such a great French mentor at @fredhutch Thank you @emilyliangmd for the picture ! Et merci à l'hemato de Roubaix de me remplacer en Hdj ! #Tandem24
Proud of Dr. @NGazeau14 who received today the 2023 Robert Korngold Award for the Best Clinical Science article published in @ASTCT_Journal Link to the publication: lnkd.in/gPydVh5v Congrats again Nicolas and thanks to all collaborators! #Tandem24 @ASTCT Photo credit:…
Congrats to Fred Hutch physician-scientist Dr. @ekimblepl on receiving a $100,000 award from @ASGCTherapy to support his work improving the effectiveness of #CARTcell therapies against #AML! bit.ly/42Fjsao
Published just in time! 🎅🎁🤗 Another fruitful collaborative exercise wtihin the @t2evolve_imi initiative! 💫 Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. frontiersin.org/articles/10.33…
Extremely proud of Dr. @NGazeau14 who was selected to receive the 2023 Robert Korngold Award for the Best Clinical Science in Cellular Therapy article by a new investigator. Dr. Gazeau steered the work leading to the @ASTCT_Journal publication "Anakinra for Refractory Cytokine…
Hello world! 👋 Find below CAR T-cell therapy-related research from our group(s) @fredhutch @UWMedicine to be presented at #ASH23 condensed in one 🧵😄 @ASH_hematology #TcellRx #CARTcells 1/18
This abstract relates to the FDA report on T cell lymphoma after CAR-T. Unfortunately it was not selected as an abstract for presentation at the ASH annual meeting and is an "online publication" only. @MoffittNews @MichaelDJain @ASH_hematology sciencedirect.com/science/articl…
Very important work from our group led by Dr. Hirayama @xanhira demonstrating that the effects of PD-L1 blockade on CD19 CAR-T efficacy/toxicity are timing-dependent (pre versus post CAR-T infusion) in LBCL patients.
Timing of Anti-PD-L1 Antibody Initiation Affects Efficacy/Toxicity of CD19 CAR-T Cell Therapy for Large B-Cell Lymphoma ashpublications.org/bloodadvances/… @fredhutch, @ekimblepl, @drjgauthier, @NGazeau14, @mshadman
Timing of Anti-PD-L1 Antibody Initiation Affects Efficacy/Toxicity of CD19 CAR-T Cell Therapy for Large B-Cell Lymphoma ashpublications.org/bloodadvances/… @fredhutch, @ekimblepl, @drjgauthier, @NGazeau14, @mshadman
Timing of Anti-PD-L1 Antibody Initiation Affects Efficacy/Toxicity of CD19 CAR-T Cell Therapy for Large B-Cell Lymphoma ashpublications.org/bloodadvances/…
Epco + RminiCHOP in 1L LBCL #ASH23: - 28 pts, median age 81 - median f/u only 6 mos - early ORR 100% (CR 85%), median time to response 1.4 mos - 1 Gr5 AE, 43% CRS (4% Gr3), no ICANS Promising work for older adults! #lymsm #gerionc ash.confex.com/ash/2023/webpr…
United States Trends
- 1. Dalton Knecht 44,4 B posts
- 2. Lakers 58,9 B posts
- 3. #LakeShow 5.343 posts
- 4. Spurs 17,1 B posts
- 5. $QUANT 9.326 posts
- 6. #DWTS 26,6 B posts
- 7. Jay Leno 3.934 posts
- 8. Hampton Inn 1.708 posts
- 9. Linda McMahon 42 B posts
- 10. Jaguar 111 B posts
- 11. #RHOBH 10,8 B posts
- 12. Cavs 52 B posts
- 13. Dorit 5.365 posts
- 14. Celtics 59,1 B posts
- 15. Kam Jones 1.991 posts
- 16. Cenk 30,6 B posts
- 17. Reaves 5.444 posts
- 18. Chase U 6.042 posts
- 19. Chris Paul 2.956 posts
- 20. Keldon Johnson 3.465 posts
Who to follow
-
Vincent Alcazer
@AlcazerVincent -
Rémy Duléry
@RemyDulery -
Association des Internes en Hématologie
@AIHemato -
Thomas Cluzeau
@thomas_cluzeau -
J.J. Kiladjian
@jjkiladjian -
Boissel Nicolas
@NicBoissel -
Aurore Perrot
@PerrotAurore -
Nicolas Stocker
@NStockerSAT -
Anaïs Schavgoulidze
@ASchavgoulidze -
Roch Houot
@HouotRoch -
Vivre Avec Une NMP
@VivreAvecUneNmp -
Anisiia Luchkiv
@anisiia_luchkiv -
Hemato à la Une
@HematoLa -
Bruno Quesnel
@QuesnelBruno1 -
Nicolas Vallet
@nivallet
Something went wrong.
Something went wrong.